Foulkes WD - Search Results

1

Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.

Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA; kConFab; Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes WD. Tischkowitz M, et al. Among authors: foulkes wd. Eur J Hum Genet. 2008 Jul;16(7):820-32. doi: 10.1038/ejhg.2008.13. Epub 2008 Feb 20. Eur J Hum Genet. 2008. PMID: 18285836 Free PMC article.

2

Survival of patients with breast cancer and BRCA1 mutations.

Foulkes WD, Wong N, Rozen F, Brunet JS, Narod SA. Foulkes WD, et al. Lancet. 1998 May 2;351(9112):1359-60. doi: 10.1016/S0140-6736(05)79091-7. Lancet. 1998. PMID: 9643825 No abstract available.

3

BRCA mutations and survival in breast cancer.

Foulkes WD, Wong N, Brunet JS, Narod SA. Foulkes WD, et al. J Clin Oncol. 1998 Sep;16(9):3206-8. doi: 10.1200/JCO.1998.16.9.3206. J Clin Oncol. 1998. PMID: 9738598 No abstract available.

4

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA. Tonin PN, et al. Among authors: foulkes wd. Am J Hum Genet. 1998 Nov;63(5):1341-51. doi: 10.1086/302099. Am J Hum Genet. 1998. PMID: 9792861 Free PMC article.

5

Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.

Foulkes WD, Wong N, Brunet JS, Bégin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, Pollak MN. Foulkes WD, et al. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2465-9. Clin Cancer Res. 1997. PMID: 9815648

6

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S. Warner E, et al. J Natl Cancer Inst. 1999 Jul 21;91(14):1241-7. doi: 10.1093/jnci/91.14.1241. J Natl Cancer Inst. 1999. PMID: 10413426

7

The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer.

Yuan ZQ, Bégin LR, Wong N, Brunet JS, Trifiro M, Gordon PH, Pinsky L, Foulkes WD. Yuan ZQ, et al. Among authors: foulkes wd. Br J Cancer. 1999 Nov;81(5):850-4. doi: 10.1038/sj.bjc.6690775. Br J Cancer. 1999. PMID: 10555757 Free PMC article.

8

No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck.

Hamel N, Black MJ, Ghadirian P, Foulkes WD. Hamel N, et al. Among authors: foulkes wd. Br J Cancer. 2000 Feb;82(4):757-9. doi: 10.1054/bjoc.1999.0993. Br J Cancer. 2000. PMID: 10732740 Free PMC article.

9

Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.

Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR. Foulkes WD, et al. Ann Oncol. 2000 Mar;11(3):307-13. doi: 10.1023/a:1008340723974. Ann Oncol. 2000. PMID: 10811497 Free article.

10

Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD. Chappuis PO, et al. Among authors: foulkes wd. J Clin Oncol. 2000 Dec 15;18(24):4045-52. doi: 10.1200/JCO.2000.18.24.4045. J Clin Oncol. 2000. PMID: 11118465

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

737 results

Search Page